Biomedical papers, 2016 (vol. 160), issue 4

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016, 160(4):543-548 | 10.5507/bp.2016.042

The safety and efficacy of Heparin and Nadroparin compared to placebo in acute ischemic stroke - pilot study

Jana Dluhaa, Stefan Sivaka, Egon Kurcaa, Robert Dusenkab, Klaudia Kalmarovaa, Monika Turcanova Koprusakovaa, Ema Kantorovaa, Vladimir Nosala
a Clinic of Neurology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava and University Hospital in Martin, Slovak Republic
b Clinic of Urology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava and University Hospital in Martin, Slovak Republic

Aims: This study aimed to compare the efficacy and safety of heparin and nadroparin in order to provide an additional therapeutic option for patients with acute ischemic stroke in, whom systemic thrombolysis was excluded, or thrombectomy could not be performed.

Methods: We describe a prospective randomized double-blind placebo-controlled pilot study in acute ischemic stroke. The therapeutic window was between 4.5 and 24 h after the onset of stroke. During the first 24 h of treatment, the patients divided into 3 groups received placebo, heparin or nadroparin (in therapeutic doses). During the following 48 h, each patient received nadroparin in the therapeutic dose. 24 h after start of treatment they began taking 100 mg aspirin daily. The primary safety indicator was incidence of complications such as intracerebral or systemic hemorrhage, or death. Efficacy was primarily monitored by the neurological modified Rankin Scale (mRS) at 90 days.

Results: There were no signs of intracerebral or systemic bleeding in the cohort of 87 patients. Two patients died - one (3.7%) in the heparin and one (3.8%) in the placebo group due to causes not connected with the treatment. There was a statistically significant difference in mRS on the 90th day between the heparin and placebo groups (21 (80%) vs 13 (50%), P=0.0350) and between the nadroparin and placebo groups (29 (85%) vs 13 (50%), P=0.0031).

Conclusion: The results show that the treatment with heparin and nadroparin is safe and effective. Trial registration: Trial is registered in ClinicalTrials.gov: NCT01862978.

Keywords: Key words: acute ischemic stroke, nadroparin, heparin, safety, efficacy, mRS

Received: June 23, 2016; Accepted: August 3, 2016; Prepublished online: September 19, 2016; Published: December 12, 2016


References

  1. Bonita R, Stewart A, Beaglehole R. International trends in stroke mortality: 1970-1985. Stroke 1990;21:989-92. Go to original source... Go to PubMed...
  2. Feigin VL, Lawes CMM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case fatality in the late 20th century. Lancet Neurol 2003;2(1):43-53. Go to original source... Go to PubMed...
  3. Hankey GJ, Warlow C. Treatment and second prevention of stroke: evidence, costs and effects on individuals and populations. Lancet 1999;354(9188):1457-63. Go to original source... Go to PubMed...
  4. Rödén-Jüllig Å, Britton M. Effectiveness of heparin treatment for progressing ischaemic stroke: before and after study. J Intern Med 2000;248(4):287-91. Go to original source... Go to PubMed...
  5. Bejot Y, Rouaud O, Durier J. Decrease in the stroke case fatality rates in a French population-based twenty-year study. Cerebrovasc Dis 2007;24:439-44. Go to original source... Go to PubMed...
  6. Tissue Plasminogen Activator for Acute Ischemic Stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333(24):1581-7. Go to PubMed...
  7. Hacke W, Kaste M, Bluhmki E. Thrombolysis Alteplase 3 to 4,5 Hours after Acute Ischemic Stroke. N Eng J Med 2008;359(13):1317-29. Go to original source... Go to PubMed...
  8. Berkhemer OA, Fransen PS, Beumer D. A randomized trial of intraarterial treatment for acute ischemic stroke. New England Journal of Medicine 2015;372:11-20. Go to original source... Go to PubMed...
  9. Campbell BCV, Mitchell PT, Kleining TJ. Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection. N Engl J Med 2015;372(11)-1009-18.
  10. Goyal M, Demchuk AM, Menon BK. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372(11):1019-30. Go to original source... Go to PubMed...
  11. Marsh EE, Adams HP, Biller J, Wasek P, Banwart K, Mitchell V, Woolson R. (1989). Use of antithrombotic drugs in the treatment of acute ischemic stroke A survey of neurologists in practice in the United States. Neurology 1989;39(12):1631-4. Go to original source... Go to PubMed...
  12. Bath P, Leonardi-Bee J, Bath F. Low molecular weight heparin versus aspirin for acute ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis 2002;11(2):55-62. Go to original source... Go to PubMed...
  13. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study: HAEST Study Group: Heparin in Acute Embolic Stroke Trial. Lancet 2000;355(9211):1205-10. Go to original source... Go to PubMed...
  14. Camerlingo M, Salvi P, Belloni G. Intravenous Heparin Started Within the First 3 Hours After Onset of Symptoms as a Treatment for Acute Nonlacunar Hemispheric Cerebral Infrartions. Stroke 2005;36(11):2415-20. Go to original source... Go to PubMed...
  15. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349(9065):1569-81.
  16. Kay R, Wong KS, Yu YL. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333(24):1588-94. Go to original source... Go to PubMed...
  17. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007;38(2):423-30. Go to original source... Go to PubMed...
  18. Rothwell PM, Coull AJ, Giles MF. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004;363(9425):1925-33. Go to original source... Go to PubMed...
  19. Sandercock PA, Counsell C, Kamal AK. Anticoagulants for acute ischeaemic stroke. Cochrane Database Syst Rev 2008;(4):CD000024.
  20. European Stroke Organisation (ESO) Executive Committee, and ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25(5):457-507. Go to original source... Go to PubMed...
  21. Jauch EC, Saver JL, Adams HP. Guidelines for the early management of patients with acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44(3):870-947. Go to original source... Go to PubMed...
  22. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke: A Randomized Controlled Trial. JAMA 1998;279(16):1265-72. Go to original source... Go to PubMed...
  23. Wang Q, Chen C, Chen XY. Low-molecular-weight heparin and early neurologic deterioration in acute stroke caused by large artery occlusive disease. Arch Neurol 2012; 69(11):1454-60. Go to original source... Go to PubMed...